within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G01A_AntiinfectivesAndAntisepticsExclCombinationsWith.G01AA07_Oxytetracycline;

model Oxytetracycline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.000000000000001e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.010199999999999999,
    k12 = 2.4444444444444445e-07,
    k21 = 2.4444444444444445e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Oxytetracycline</td></tr><tr><td>ATC code:</td><td>G01AA07</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Oxytetracycline is a broad-spectrum tetracycline-class antibiotic that is primarily used to treat a variety of bacterial infections. It has been used in human and veterinary medicine for respiratory tract infections, urinary tract infections, and other bacterial diseases. It is authorized for use but its clinical use in humans has decreased due to the emergence of resistance and availability of alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Winter, EA, et al., &amp; Gehring, R (2024). Determination of pharmacokinetic-pharmacodynamic cutoff values of oxytetracycline in calves and adult cattle using population pharmacokinetic modeling. <i>Frontiers in microbiology</i> 15 1498219–None. DOI:<a href=\"https://doi.org/10.3389/fmicb.2024.1498219\">10.3389/fmicb.2024.1498219</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39697656/\">https://pubmed.ncbi.nlm.nih.gov/39697656</a></p></li><li><p>Riad, MH, et al., &amp; Lin, Z (2021). Development and Application of an Interactive Physiologically Based Pharmacokinetic (iPBPK) Model to Predict Oxytetracycline Tissue Distribution and Withdrawal Intervals in Market-Age Sheep and Goats. <i>Toxicological sciences : an official journal of the Society of Toxicology</i> 183(2) 253–268. DOI:<a href=\"https://doi.org/10.1093/toxsci/kfab095\">10.1093/toxsci/kfab095</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34329480/\">https://pubmed.ncbi.nlm.nih.gov/34329480</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G01AA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Oxytetracycline;
